Home   Distributors   Careers   Contact

 

DESyne® BD NOVOLIMUS™ Eluting Coronary Stent System

The Elixir DESyne BD Novolimus-Eluting Coronary Stent System represents a significant advancement in biodegradable coating technology, eliminating the need for a primer coating and achieving a bare metal surface within 6 -9 months, while providing excellent DES results.

Stent Design

Cobalt Chromium Platform

The DESyne BD stent is manufactured on a clinically-proven cobalt chromium platform to maximize deliverability.

  • Lowest profile stent design with ultra-thin struts (81 microns) for high flexibility and deliverability
  • Substantial vessel wall coverage for uniform drug delivery and open cell design for ease of side branch access

 

Biodegradable Polymer Coating

Biodegradable Polymer Coating

  • Ultra-thin biodegradable polymer dissolves within 6-9 months
  • Trusted polylactide-based polymer

Low Drug Dose

  • Sustainable performance with lower drug dose

Established Safety and Performance

  • Clinically proven ‘olimus’ drug family
  • Active metabolite of Sirolimus

Proprietary Drug Facilitates Superior Clinical Efficacy1

  • Potent anti-proliferative agent

Safety Profile

Elixir conducted five separate trials which included over 400 patients for the prevention of restenosis using DESyne and DEsyne BD stent systems resulting in excellent and sustained safety and effectiveness clinical outcomes.

Clinical Data

Elixir Medical has completed the EXCELLA BD randomized trial for the DESyne BD Novolimus-Eluting Stent System. 
The EXCELLA BD Trial was a randomized, prospective, multicenter, single-blind, non-inferiority study evaluating the DESyne® BD Novolimus Eluting Coronary Stent System (CSS) with resorbable polylactide-based polymer compared to the Endeavor Zotarolimus Eluting Coronary Stent System. 

Learn more about EXCELLA BD

1 » Serruys, P.W. et. al, EuroIntervention 2010.

2 » As compared to manufacturer reported thickness for Xience V® and Resolute®. Data on file at Elixir Medical.

3 » Data on file at Elixir Medical.

4 » As compared to manufacturer reported late lumen loss at follow up from similar trials. Data on file at Elixir Medical.

5 » SIRIUS: Weisz, G. et. al., JACC 2006 ; RESOLUTE: Serruys, P.W., EuroPCR 2009 ; SPIRIT III: Stone, G. W., Circulation 2009.